Initial Dosing in Therapy of Chronic Viral Hepatitis C

Purpose: To plan the initial dosing of Copegus (ribavirin) and Pegasys (pegylated interferon alfa-2b) for a patient with chronic viral hepatitis C.

Info MyLikes MyPaths

Evaluation

Are you planning to treat a patient with chronic viral hepatitis C?

Yes

Body weight

Does the patient have heart disease?

Yes

Creatinine clearance

mL/min

Genotype of viral hepatitis C

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Is therapy with Copegus and Pegasys contraindicated in the patient?

Daily dose of Pegasys

Daily dose of Copegus

Duration of therapy

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
- Hepatitis C Virus and HIV | Risk Factors for Hepatic Decompensation During Interferon-Ribavirin Therapy

Therapy

Pharmacogenetics
Dosage Calculations
Dosage Adjustments
- Chronic Viral Hepatitis C | Adjusting Dose of Copegus (Ribavirin)
- Chronic Viral Hepatitis C | Adjusting Dose of Interferon alfa-2b
Failure Handling And Therapy Escalation
- Primary Nonresponsiveness to Hepatitis B Virus Vaccine
Prevention

Monitoring

Response To Therapy
- Primary Nonresponsiveness to Hepatitis B Virus Vaccine
Adverse Effects
- Hepatitis C Virus and HIV | Risk Factors for Hepatic Decompensation During Interferon-Ribavirin Therapy
Compliance/adherence
- Vaccination Against Viral Hepatitis A & B in Patient with Chronic Liver Disease (CLD)

Societal Concerns

Public Health
- Vaccination Against Viral Hepatitis A & B in Patient with Chronic Liver Disease (CLD)

Specialty

Infectious Diseases
Pharmacology, clinical
Gastroenterology

Objective

pharmacogenetics
dosage calculations

ICD-10

B18.2 - Chronic viral hepatitis C

Info

Purpose: To plan the initial dosing of Copegus (ribavirin) and Pegasys (pegylated interferon alfa-2b) for a patient with chronic viral hepatitis C.

Specialty: Infectious Diseases, Pharmacology, clinical, Gastroenterology

Objective: pharmacogenetics, dosage calculations

ICD-10: B18.2,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path